HIV/AIDS Prevention in Central Africa, Phase V (Projects)
https://www.swisstph.ch/de/projects/project-detail/project/hiv/aids-prevention-in-central-africa-phase-v
Background HIV/AIDS remains a major public health threat in the Central African Region. Given that condom use is a highly cost-effective intervention, the phase V of the HIV/AIDS prevention program ("
Transportation Noise: Quantitative Methods for Investigating Acute and Long Term Health Effects (Projects)
https://www.swisstph.ch/de/projects/project-detail/project/transportation-noise-quantitative-methods-for-investigating-acute-and-long-term-health-effects
Background: Noise from road, railway and aircraft traffic is one of the most widespread sources of environmental stress and discomfort in everyday life. However, previous research has been fragmented,
Effects of Low-Level Air Pollution: A study in Europe (Projects)
https://www.swisstph.ch/de/projects/project-detail/project/effects-of-low-level-air-pollution-a-study-in-europe
ELAPSE (Effects of Low-Level Air Pollution: A Study in Europe) is a Europe-wide collaboration in a research project Mortality and morbidity effects of long-term exposure to low-level PM2.5, Black Carb
Master of Advanced studies in Insurance Medicine (Projects)
https://www.swisstph.ch/de/projects/project-detail/project/master-of-advanced-studies-in-insurance-medicine
The MAS Insurance Medicine is a postgraduate programme of the university of Basel under the sponsorship of the Swiss Tropical and Public Health Institute (Swiss TPH). The programme is carried out by S
Thermotherapy of Buruli Ulcer at Community Level, Cameroon (Projects)
https://www.swisstph.ch/de/projects/project-detail/project/thermotherapy-of-buruli-ulcer-at-community-level-cameroon
Treatment of the neglected tropical skin disease Buruli Ulcer (BU) relies currently on a single drug, rifampicin, which is given in combination with streptomycin. Development of an alternative treatme
Lufthygienische Dokumentationsstelle 2018-2021 (Projects)
https://www.swisstph.ch/de/projects/project-detail/project/lufthygienische-dokumentationsstelle-2018-2021
Die vom Bundesamt für Umwelt (BAFU) finanzierte Dokumentationsstelle LUDOK am Schweizerischen Tropen und Public Health Institut (Swiss TPH) liefert seit 30 Jahren evidenzbasierte Informationen zu den
Efficacy and safety of fexinidazole in patients with Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense: a multicentre,... (Projects)
https://www.swisstph.ch/de/projects/project-detail/project/efficacy-and-safety-of-fexinidazole-in-patients-with-human-african-trypanosomiasis-hat-due-to-trypanosoma-brucei-rhodesiense-a-multicentre-open-label-clinical-trial
A vector-borne parasitic illness, human African trypanosomiasis (HAT), also known as sleeping sickness, is usually fatal without treatment. The less prevalent form, T.b. rhodesiense (r-HAT), is concen
Drug discovery and development for schistosomiasis: From repositioning of antimalarial drug leads and clinical advanced drug candidates to the... (Projects)
https://www.swisstph.ch/de/projects/project-detail/project/drug-discovery-and-development-for-schistosomiasis-from-repositioning-of-antimalarial-drug-leads-and-clinical-advanced-drug-candidates-to-the-development-of-a-new-paediatric-formulation-of-praziquantel
The aim of my 4-year research project is to identify one or several antischistosomal drug development candidates targeting the haemoglobin degradation pathway and/or other mechanisms with favourable p
Infected body on a chip”: Microfluidic impedance platform for antischistosomal drug discovery (Projects)
https://www.swisstph.ch/de/projects/project-detail/project/infected-body-on-a-chip-microfluidic-impedance-platform-for-antischistosomal-drug-discovery
Many new methods in drug discovery originate from the field of microfluidics, which also include innovative methods to monitor the status of cells or tissues by means of electric impedance spectroscop
